It was assumed that virtually all types of epithelial malignancies are characterized by some involvement of EGFR activation, therefore EGFR-directed therapies were expected to be efficient in a wide spectrum of cancers (Nicholson et al., 2001; Baselga, 2002). The gene discussed is EGFR; the disease is cancer.